<!DOCTYPE html>
    <html>
    <head>
        <meta charset="UTF-8">
        <title>Welcome</title>
        <style>
</style>
        
        <link rel="stylesheet" href="https://cdn.jsdelivr.net/gh/Microsoft/vscode/extensions/markdown-language-features/media/markdown.css">
<link rel="stylesheet" href="https://acc-style.github.io/Arches/css/acc_uc.min.css">
<style>
            body {
                font-family: -apple-system, BlinkMacSystemFont, 'Segoe WPC', 'Segoe UI', system-ui, 'Ubuntu', 'Droid Sans', sans-serif;
                font-size: 14px;
                line-height: 1.6;
            }
        </style>
        <style>
.task-list-item { list-style-type: none; } .task-list-item-checkbox { margin-left: -20px; vertical-align: middle; }
</style>
        
        
        
    </head>
    <body class="vscode-body vscode-light reading-typography lh_2 m_auto max-w_40">
        <h1 class="font_bold"id="welcome">Welcome</h1>
<p class="lh_1"><strong>7:45 a.m. – 8:00 a.m.</strong><br>
<strong>Cathleen C. Gates</strong><br>
<strong>Interim, Chief Executive Officer</strong><br>
<em class="c_black-7 font-size_down">American College of Cardiology</em><br>
<strong>Athena Poppas, MD, FACC</strong><br>
<strong>President</strong><br>
<em class="c_black-7 font-size_down">American College of Cardiology</em><br>
<strong>Norma Keller, MD, FACC</strong><br>
<strong>President, New York State Chapter</strong><br>
<em class="c_black-7 font-size_down">American College of Cardiology</em></p>
<hr class="br-t_1 br_0 br_dashed br_primary m-y_5 m-x_n2">
<h1 class="font_bold"id="cardiovascular--coronary-artery-disease--challenges-in-2020">Cardiovascular &amp; Coronary Artery Disease — Challenges in 2020</h1>
<h2 class="font_medium c_acc-n2" id="session-i-evolving-new-frontiers-ready-for-practice">Session I: Evolving New Frontiers Ready for Practice</h2>
<p class="lh_1"><strong>Chair: Athena Poppas, MD, FACC</strong>*</p>
<hr class="br-t_1 br_0 br_dashed br_primary m-y_5 m-x_n2">
<p class="m-b_2"><strong class="c_accent-n3">8:00 a.m. – 8:25 a.m.</strong></p>
<h3 class="m-t_0 c_acc font_display font_medium  lh_2" id="clinical-genetic--noninvasive-imaging-3d-us-pet-mri-stratification-predicting-progression-of-cvd-and-cognitive-dysfunction">Clinical, Genetic &amp; Noninvasive Imaging (3D-US, PET, MRI) Stratification Predicting Progression of CVD and Cognitive Dysfunction</h3>
<p class="lh_1"><strong>Valentin Fuster, MD, PhD, MACC</strong><br>
<em class="c_black-7 font-size_down">New York, NY</em></p>
<hr class="br-t_1 br_0 br_dashed br_primary m-y_5 m-x_n2">
<p class="m-b_2"><strong class="c_accent-n3">8:25 a.m. – 8:50 a.m.</strong></p>
<h3 class="m-t_0 c_acc font_display font_medium  lh_2" id="cta-imaging-in-the-full-assessment-of-coronary-disease">CTA Imaging in the Full Assessment of Coronary Disease</h3>
<p class="lh_1">Noninvasive Approach to Plaque Anatomy, Ischemia &amp; Risk<br>
<strong>Patrick W. Serruys, MD, FACC</strong><br>
<em class="c_black-7 font-size_down">Rotterdam, Netherlands</em></p>
<hr class="br-t_1 br_0 br_dashed br_primary m-y_5 m-x_n2">
<p class="m-b_2"><strong class="c_accent-n3">8:50 a.m. – 9:15 a.m.</strong></p>
<h3 class="m-t_0 c_acc font_display font_medium  lh_2" id="stratification-of-angina-due-to-coronary-microvascular-dysfunction-epicardial-spastic-phenomenon--inoca-in-context">Stratification of Angina due to Coronary Microvascular Dysfunction Epicardial Spastic Phenomenon &amp; INOCA in Context</h3>
<p class="lh_1"><strong>Divaka Perera, MD</strong><br>
<em class="c_black-7 font-size_down">London, England, United Kingdom</em></p>
<hr class="br-t_1 br_0 br_dashed br_primary m-y_5 m-x_n2">
<p class="m-b_2"><strong class="c_accent-n3">9:15 a.m. – 9:35 a.m.</strong></p>
<h3 class="m-t_0 c_acc font_display font_medium  lh_2" id="coronary-18f-sodium-fluoride-uptake-imaging-predicts-activity-and-outcomes-in-patients-with-coronary-disease">Coronary 18F-Sodium Fluoride Uptake Imaging Predicts Activity and Outcomes in Patients with Coronary Disease</h3>
<p class="lh_1"><strong>Marc Dweck, MB ChB, PhD, FACC</strong><br>
<em class="c_black-7 font-size_down">Edinburgh, Scotland, United Kingdom</em></p>
<hr class="br-t_1 br_0 br_dashed br_primary m-y_5 m-x_n2">
<p class="m-b_2"><strong class="c_accent-n3">9:35 a.m. – 10:00 a.m.</strong></p>
<h3 class="m-t_0 c_acc font_display font_medium  lh_2" id="panel-discussion">Panel Discussion</h3>
<p class="lh_1"><strong>Panelists: Drs. Dweck, Fuster, Perera and Serruys</strong></p>
<hr class="br-t_1 br_0 br_dashed br_primary m-y_5 m-x_n2">
<p class="m-b_2"><strong class="c_accent-n3">10:00 a.m. – 10:25 a.m.</strong></p>
<h3 class="m-t_0 c_acc font_display font_medium  lh_2" id="break">Break</h3>
<h2 class="font_medium c_acc-n2" id="session-ii-acute-coronary-syndrome-complexities">Session II: Acute Coronary Syndrome Complexities</h2>
<p class="lh_1"><strong>Chair: Deepak L. Bhatt, MD, MPH, FACC</strong></p>
<hr class="br-t_1 br_0 br_dashed br_primary m-y_5 m-x_n2">
<p class="m-b_2"><strong class="c_accent-n3">10:25 a.m. – 10:45 a.m.</strong></p>
<h3 class="m-t_0 c_acc font_display font_medium  lh_2" id="stemi---pci-complete-revascularization-vs-culprit-lesion-only-multivessel-disease-without-or-with-cardiogenic-shock">STEMI - PCI Complete Revascularization vs Culprit Lesion only Multivessel Disease Without or With Cardiogenic Shock</h3>
<p class="lh_1"><strong>Shamir Mehta, MD, FACC</strong><br>
<em class="c_black-7 font-size_down">Hamilton, ON, Canada</em></p>
<hr class="br-t_1 br_0 br_dashed br_primary m-y_5 m-x_n2">
<p class="m-b_2"><strong class="c_accent-n3">10:45 a.m. – 11:05 a.m.</strong></p>
<h3 class="m-t_0 c_acc font_display font_medium  lh_2" id="covid-19---acute-coronary--myocardial-syndromes--follow-up-certainties--uncertainties-on-incidence-pathogenesis--management">COVID 19 - Acute Coronary / Myocardial Syndromes &amp; Follow Up Certainties &amp; Uncertainties on Incidence, Pathogenesis &amp; Management</h3>
<p class="lh_1"><strong>Deepak L. Bhatt, MD, MPH, FACC</strong><br>
<em class="c_black-7 font-size_down">Boston, MA</em></p>
<hr class="br-t_1 br_0 br_dashed br_primary m-y_5 m-x_n2">
<p class="m-b_2"><strong class="c_accent-n3">11:05 a.m. – 11:35 a.m.</strong><br></p>
<h3 class="m-t_0 c_acc font_display font_medium  lh_2" >Antithrombotics in High vs Low Risk Patients &amp; with vs Without PCI Evolving Path Towards Monotherapy - For How Long, P2Y12 Inhib.? vs NOACS</h3>
<p class="lh_1"></p><strong>Roxana Mehran, MD, FACC</strong><br>
<em class="c_black-7 font-size_down">New York, NY</em></p>
<hr class="br-t_1 br_0 br_dashed br_primary m-y_5 m-x_n2">
<p class="m-b_2"><em class="c_black-7 font-size_down">11:35 a.m. – 12:00 Noon</em></p>
<h3 class="m-t_0 c_acc font_display font_medium  lh_2" id="panel-discussion-1">Panel Discussion</h3>
<p class="lh_1"><strong>Panelists: Drs. Bhatt, Mehran and Mehta</strong></p>
<hr class="br-t_1 br_0 br_dashed br_primary m-y_5 m-x_n2">
<p class="m-b_2"><strong class="c_accent-n3">12:00 Noon – 1:00 p.m.</strong></p>
<h3 class="m-t_0 c_acc font_display font_medium  lh_2" id="lunch-break">Lunch Break</h3>
<h2 class="font_medium c_acc-n2" id="session-iii-chronic-coronary-disease-systemic-arterial-disease-stroke-and-pulmonary-embolism">Session III: Chronic Coronary Disease, Systemic Arterial Disease, Stroke and Pulmonary Embolism</h2>
<p class="lh_1"><strong>Chair: Dipti Itchhaporia, MD, FACC</strong></p>
<hr class="br-t_1 br_0 br_dashed br_primary m-y_5 m-x_n2">
<p class="m-b_2"><em class="c_black-7 font-size_down">1:00 p.m. – 1:25 p.m.</strong></p>
<h3 class="m-t_0 c_acc font_display font_medium  lh_2" id="stable-coronary-multivessel-disease-five-variables---clinical-anatomy-lv-ischemia-microcirculation-three-approaches-of-managements---pci-vs-cabg-vs-omt">Stable Coronary Multivessel Disease Five Variables - Clinical, Anatomy, LV, Ischemia, Microcirculation Three Approaches of Managements - PCI vs CABG vs OMT</h3>
<p class="lh_1"><strong>Valentin Fuster, MD, PhD, MACC</strong><br>
<em class="c_black-7 font-size_down">New York, NY</em></p>
<hr class="br-t_1 br_0 br_dashed br_primary m-y_5 m-x_n2">
<p class="m-b_2"><strong class="c_accent-n3">1:25 p.m. – 1:50 p.m.</strong></p>
<h3 class="m-t_0 c_acc font_display font_medium  lh_2" id="coronary--systemic-arterial-disease--the-role-of-new-oral-anticoagulants-noacs">Coronary &amp; Systemic Arterial Disease – The Role of New Oral Anticoagulants (NOACS)</h3>
<p class="lh_1"><strong>John Eikelboom, MBBS</strong></p>
<p class="lh_1"><em class="c_black-7 font-size_down">Hamilton, ON, Canada</em></p>
<hr class="br-t_1 br_0 br_dashed br_primary m-y_5 m-x_n2">
<p class="m-b_2"><strong class="c_accent-n3">1:50 p.m. – 2:15 p.m.</strong></p>
<h3 class="m-t_0 c_acc font_display font_medium  lh_2" id="ischemic-strokes--cerebral-hemorrhage-acute-management-vs-primary--secondary-prevention">Ischemic Strokes &amp; Cerebral Hemorrhage Acute Management vs Primary &amp; Secondary Prevention</h3>
<p class="lh_1"><strong>Priyank Khandelwal, MD</strong><br>
<em class="c_black-7 font-size_down">Newark, NJ</em></p>
<hr class="br-t_1 br_0 br_dashed br_primary m-y_5 m-x_n2">
<p class="m-b_2"><strong class="c_accent-n3">2:15 p.m. – 2:40 p.m.</strong></p>
<h3 class="m-t_0 c_acc font_display font_medium  lh_2" id="pulmonary-emboli---diagnosis-based-on-suspicion-management-based-on-the-acute-severity-and-degree-of-chronic-ph">Pulmonary Emboli - Diagnosis Based on Suspicion Management Based on the Acute Severity and Degree of Chronic PH</h3>
<p class="lh_1"><strong>Samuel Z. Goldhaber, MD, FACC</strong><br>
<em class="c_black-7 font-size_down">Boston, MA</em></p>
<hr class="br-t_1 br_0 br_dashed br_primary m-y_5 m-x_n2">
<p class="m-b_2"><strong class="c_accent-n3">2:40 p.m. – 3:05 p.m.</strong></p>
<h3 class="m-t_0 c_acc font_display font_medium  lh_2" id="panel-discussion-2">Panel Discussion</h3>
<p class="lh_1"><strong>Panelists: Drs. Eikelboom, Fuster, Goldhaber and Khandelwal</strong></p>
<hr class="br-t_1 br_0 br_dashed br_primary m-y_5 m-x_n2">
<p class="m-b_2"><strong class="c_accent-n3">3:05 p.m. – 3:30 p.m.</strong></p>
<h3 class="m-t_0 c_acc font_display font_medium  lh_2" id="break-1">Break</h3>
<h2 class="font_medium c_acc-n2" id="session-iv-trends-and-challenges-of-approaching-prevention--health-factors">Session IV: Trends and Challenges of Approaching Prevention – Health Factors</h2>
<p class="lh_1"><strong>Chair: Pamela B. Morris, MD, FACC</strong><br>
<strong>3:30 p.m. – 3:55 p.m.</strong></p>
<h3 class="m-t_0 c_acc font_display font_medium  lh_2" id="obesity--from-genetics--behavior-to-pharmacotherapy--bariatric-surgery">Obesity – From Genetics &amp; Behavior to Pharmacotherapy &amp; Bariatric Surgery</h3>
<p class="lh_1"><strong>Carl J. Lavie, MD, FACC</strong><br>
<em class="c_black-7 font-size_down">New Orleans, LA</em></p>
<hr class="br-t_1 br_0 br_dashed br_primary m-y_5 m-x_n2">
<p class="m-b_2"><strong class="c_accent-n3">3:55 p.m. – 4:20 p.m.</strong></p>
<h3 class="m-t_0 c_acc font_display font_medium  lh_2" id="lipid-modifying-agents---from-statins-to-pcsk9-inhibitors">Lipid-Modifying Agents - From Statins to PCSK9 Inhibitors</h3>
<p class="lh_1"><strong>Neil J. Stone, MD, FACC</strong><br>
<em class="c_black-7 font-size_down">Chicago, IL</em></p>
<hr class="br-t_1 br_0 br_dashed br_primary m-y_5 m-x_n2">
<p class="m-b_2"><strong class="c_accent-n3">4:20 p.m. – 4:45 p.m.</strong></p>
<h3 class="m-t_0 c_acc font_display font_medium  lh_2" id="diabetic-agents--from-metformin-to-sglt2-inhib--glp1-receptor-agonists">Diabetic Agents – From Metformin To SGLT2 Inhib. &amp; GLP1 Receptor Agonists</h3>
<p class="lh_1"><strong>David Preiss, MD, PhD</strong><br>
<em class="c_black-7 font-size_down">Oxford, England, United Kingdom</em></p>
<hr class="br-t_1 br_0 br_dashed br_primary m-y_5 m-x_n2">
<p class="m-b_2"><strong class="c_accent-n3">4:45 p.m. – 5:10 p.m.</strong></p>
<h3 class="m-t_0 c_acc font_display font_medium  lh_2" id="changing-patterns-of-mortality-and-their-causes">Changing Patterns of Mortality And Their Causes &ndash; The PURE Study in 21 Countries</h3>
<p class="lh_1"><strong>Salim Yusuf, DPhil, FACC</strong><br>
<em class="c_black-7 font-size_down">Hamilton, ON, Canada</em></p>
<hr class="br-t_1 br_0 br_dashed br_primary m-y_5 m-x_n2">
<p class="m-b_2"><strong class="c_accent-n3">5:10 p.m. – 5:35 p.m.</strong></p>
<h3 class="m-t_0 c_acc font_display font_medium  lh_2" id="the-present-global-burden-of-cardiovascular-diseases-and-risk-factors">The Present Global Burden of Cardiovascular Diseases and Risk Factors</h3>
<p class="lh_1"><strong>George A. Mensah, MD, FACC</strong><br>
<em class="c_black-7 font-size_down">Bethesda, MD</em></p>
<hr class="br-t_1 br_0 br_dashed br_primary m-y_5 m-x_n2">
<p class="m-b_2"><strong class="c_accent-n3">5:35 p.m. – 6:00 p.m.</strong></p>
<h3 class="m-t_0 c_acc font_display font_medium  lh_2" id="panel-discussion-3">Panel Discussion</h3>
<p class="lh_1"><strong>Panelists: Drs. Lavie, Mensah, Preiss, Stone and Yusuf</strong></p>
<p class="lh_1"><strong>6:00 p.m. Adjourn</strong></p>
<h1 class="font_bold"id="cardio-pulmonary-and-electrical-failure-2020">Cardio-Pulmonary and Electrical Failure 2020</h1>
<h2 class="font_medium c_acc-n2" id="session-v-myocardial-disease-and-heart-failure-basis-for-management">Session V: Myocardial Disease and Heart Failure; Basis for Management</h2>
<p class="lh_1"><strong>Chair: Clyde W. Yancy, MD, MACC</strong></p>
<hr class="br-t_1 br_0 br_dashed br_primary m-y_5 m-x_n2">
<p class="m-b_2"><strong class="c_accent-n3">8:00 a.m. – 8:20 a.m.</strong></p>
<h3 class="m-t_0 c_acc font_display font_medium  lh_2" id="evolving-imaging-mri-pet-for-7-myocardial-diseases-myocarditis-dilated-cm-hypertrophic-cm-noncompaction-lv-amyloid-cm-sarcoid--takotsubo-diagnostic--prognostic-tools">Evolving Imaging (MRI, PET) for 7 Myocardial Diseases Myocarditis, Dilated CM, Hypertrophic CM, Noncompaction LV, Amyloid CM, Sarcoid &amp; Takotsubo Diagnostic &amp; Prognostic Tools</h3>
<p class="lh_1"><strong>Jeroen J. Bax, MD, PhD, FACC</strong><br>
<em class="c_black-7 font-size_down">Leiden, Netherlands</em></p>
<hr class="br-t_1 br_0 br_dashed br_primary m-y_5 m-x_n2">
<p class="m-b_2"><strong class="c_accent-n3">8:20 a.m. – 8:40 a.m.</strong></p>
<h3 class="m-t_0 c_acc font_display font_medium  lh_2" id="evolving-clinical-genetics--omics-in-7-myocardial-diseases">Evolving Clinical Genetics &amp; Omics in 7 Myocardial Diseases</h3>
<p class="lh_1">Which Subgroup or When Should be Gene Tested<br>
<strong>William J. McKenna, MD, FACC</strong><br>
<em class="c_black-7 font-size_down">London, England, United Kingdom</em></p>
<hr class="br-t_1 br_0 br_dashed br_primary m-y_5 m-x_n2">
<p class="m-b_2"><strong class="c_accent-n3">8:40 a.m. – 9:00 a.m.</strong></p>
<h3 class="m-t_0 c_acc font_display font_medium  lh_2" id="evolving-understanding-of-hfref-vs-hfief-vs-hfpef-phenotypes-therapeutic-role-of-sglt2-inhibitors--arnis-in-the-3-entities">Evolving Understanding of HFrEF vs HFiEF vs HFpEF Phenotypes Therapeutic Role of SGLT2 Inhibitors &amp; ARNIs in the 3 Entities</h3>
<p class="lh_1"><strong>Clyde W. Yancy, MD, MACC</strong><br>
<em class="c_black-7 font-size_down">Chicago, IL</em></p>
<hr class="br-t_1 br_0 br_dashed br_primary m-y_5 m-x_n2">
<p class="m-b_2"><strong class="c_accent-n3">9:00 a.m. – 9:20 a.m.</strong></p>
<h3 class="m-t_0 c_acc font_display font_medium  lh_2" id="evolving-therapeutic-approaches-to-4-challenging-cardiomyopathies-myocarditis-takotsubo-alttr-amyloid-and-non-compaction-lv">Evolving Therapeutic Approaches to 4 Challenging Cardiomyopathies: Myocarditis, Takotsubo, AL/TTR Amyloid and Non-Compaction LV</h3>
<p class="lh_1"><strong>Matthew S. Maurer, MD, FACC</strong><br>
<em class="c_black-7 font-size_down">New York, NY</em></p>
<hr class="br-t_1 br_0 br_dashed br_primary m-y_5 m-x_n2">
<p class="m-b_2"><strong class="c_accent-n3">9:20 a.m. – 9:40 a.m.</strong></p>
<h3 class="m-t_0 c_acc font_display font_medium  lh_2" id="assist-devices-in-cardiac-decompensation--the-2-challenges">Assist Devices in Cardiac Decompensation – The 2 Challenges:</h3>
<pre>1. LVAD Indications: Not to Early since Risks are High, but Not too Late,
2. Assist Devices in the acute Decompensation – Impella vs ECMO
</pre>
<h3 class="m-t_0 c_acc font_display font_medium  lh_2" id="sean-p-pinney-md-facc">Sean P. Pinney, MD, FACC</h3>
<p class="lh_1"><em class="c_black-7 font-size_down">Chicago, IL</em></p>
<hr class="br-t_1 br_0 br_dashed br_primary m-y_5 m-x_n2">
<p class="m-b_2"><strong class="c_accent-n3">9:40 a.m. – 10:10 a.m.</strong></p>
<h3 class="m-t_0 c_acc font_display font_medium  lh_2" id="panel-discussion-4">Panel Discussion</h3>
<p class="lh_1"><strong>Panelists: Drs. Bax, Maurer, McKenna, Pinney and Yancy</strong></p>
<hr class="br-t_1 br_0 br_dashed br_primary m-y_5 m-x_n2">
<p class="m-b_2"><strong class="c_accent-n3">10:10 a.m. – 10:35 a.m.</strong></p>
<h3 class="m-t_0 c_acc font_display font_medium  lh_2" id="break-2">Break</h3>
<hr class="br-t_1 br_0 br_dashed br_primary m-y_5 m-x_n2">
<h2 class="font_medium c_acc-n2" id="session-vi-rhythm-disorders-contemporary-and-future-topics-of-focus">Session VI: Rhythm Disorders, Contemporary and Future Topics of Focus</h2>
<p class="lh_1"><strong>Chair: Vivek Y. Reddy, MD</strong><br>
<strong>10:35 a.m. – 11:00 a.m.</strong></p>
<h3 class="m-t_0 c_acc font_display font_medium  lh_2" id="atrial-fibrillation-2020--14-clinical-challenges-quality-of-life--preventing-stroke">Atrial Fibrillation 2020 – 14 Clinical Challenges Quality of Life &amp; Preventing Stroke</h3>
<p class="lh_1"><strong>Valentin Fuster, MD, PhD, MACC</strong><br>
<em class="c_black-7 font-size_down">New York, NY</em></p>
<hr class="br-t_1 br_0 br_dashed br_primary m-y_5 m-x_n2">
<p class="m-b_2"><strong class="c_accent-n3">11:00 a.m. – 11:25 a.m.</strong></p>
<h3 class="m-t_0 c_acc font_display font_medium  lh_2" id="atrial-fibrillation---catheter-ablation-who-when-how-results-cabana--others">Atrial Fibrillation - Catheter Ablation Who?, When?, How?, Results? (CABANA &amp; Others).</h3>
<p class="lh_1"><strong>Vivek Y. Reddy, MD</strong><br>
<em class="c_black-7 font-size_down">New York, NY</em></p>
<hr class="br-t_1 br_0 br_dashed br_primary m-y_5 m-x_n2">
<p class="m-b_2"><strong class="c_accent-n3">11:25 a.m. – 11:45 a.m.</strong></p>
<h3 class="m-t_0 c_acc font_display font_medium  lh_2" id="atrial-fibrillation---left-atrial-appendage-closure-who-when-how-results">Atrial Fibrillation - Left Atrial Appendage Closure Who?, When?, How?, Results?</h3>
<p class="lh_1"><strong>Jens Erik Nielsen-Kudsk, MD</strong><br>
<em class="c_black-7 font-size_down">Aarhus, Denmark</em></p>
<hr class="br-t_1 br_0 br_dashed br_primary m-y_5 m-x_n2">
<p class="m-b_2"><em class="c_black-7 font-size_down">11:45 a.m. – 12:10 p.m.</em></p>
<h3 class="m-t_0 c_acc font_display font_medium  lh_2" id="ventricular-tachycardia---catheter-ablation-who-when-how-results">Ventricular Tachycardia - Catheter Ablation Who?, When?, How?, Results?</h3>
<p class="lh_1"><strong>Karl-Heinz Kuck, MD</strong><br>
<em class="c_black-7 font-size_down">Hamburg, Germany</em></p>
<hr class="br-t_1 br_0 br_dashed br_primary m-y_5 m-x_n2">
<p class="m-b_2"><strong class="c_accent-n3">12:10 p.m. – 12:35 p.m.</strong></p>
<h3 class="m-t_0 c_acc font_display font_medium  lh_2" id="device-therapeutic-approaches-crts-strict-indications-subcutaneous-icds-leadless-pacemakers-follow-up-observations">Device Therapeutic Approaches CRTs Strict Indications, Subcutaneous ICDs, Leadless Pacemakers Follow-up Observations</h3>
<p class="lh_1"><strong>Christophe Leclercq, MD</strong><br>
<em class="c_black-7 font-size_down">Rennes, France</em></p>
<hr class="br-t_1 br_0 br_dashed br_primary m-y_5 m-x_n2">
<p class="m-b_2"><strong class="c_accent-n3">12:35 p.m. – 1:00 p.m.</strong></p>
<h3 class="m-t_0 c_acc font_display font_medium  lh_2" id="panel-discussion-5">Panel Discussion</h3>
<p class="lh_1"><strong>Panelists: Drs. Fuster, Kuck, Leclercq, Nielsen-Kudsk and Reddy</strong></p>
<hr class="br-t_1 br_0 br_dashed br_primary m-y_5 m-x_n2">
<p class="m-b_2"><strong class="c_accent-n3">1:00 p.m. – 2:00 p.m.</strong></p>
<h3 class="m-t_0 c_acc font_display font_medium  lh_2" id="lunch-break-1">Lunch Break</h3>
<hr class="br-t_1 br_0 br_dashed br_primary m-y_5 m-x_n2">
<hr class="br-t_1 br_0 br_dashed br_primary m-y_5 m-x_n2">
<h1 class="font_bold" id="valvular-heart-disease-and-aorta--challenges-in-2020">Valvular Heart Disease and Aorta — Challenges in 2020</h1>
<h3 class="m-t_0 c_acc font_display font_medium  lh_2" id="session-vii-management-of-aortic-valve-disease-and-aorta">Session VII: Management of Aortic Valve Disease and Aorta</h3>
<p class="lh_1"><strong>Chair: Rick A. Nishimura, MD, MACC</strong></p>
<hr class="br-t_1 br_0 br_dashed br_primary m-y_5 m-x_n2">
<p class="m-b_2"><strong class="c_accent-n3">2:00 p.m. – 2:30 p.m.</strong></p>
<h3 class="m-t_0 c_acc font_display font_medium  lh_2" id="aortic-valvular-stenosis-3-diagnostic-and-management-challenges-15-minutes">Aortic Valvular Stenosis: 3 Diagnostic and Management Challenges: (15 minutes)</h3>
<pre>Congenital vs Senile
Asymptomatic vs Symptomatic
Low Flow/Low Gradient: CM 2ary to AS vs Dilated vs Restrictive  
</pre>
<p class="lh_1"><strong>Robert O. Bonow, MD, MACC</strong><br>
<em class="c_black-7 font-size_down">Chicago, IL</em></p>
<hr class="br-t_1 br_0 br_dashed br_primary m-y_5 m-x_n2">
<h3 class="m-t_0 c_acc font_display font_medium  lh_2" id="critical-commentary-15-minutes">Critical Commentary: (15 minutes)</h3>
<p class="lh_1"><strong>Drs. David H. Adams, Patrick T. O’Gara, Josep Rodes-Cabau and Samin K. Sharma</strong></p>
<hr class="br-t_1 br_0 br_dashed br_primary m-y_5 m-x_n2">
<p class="m-b_2"><strong class="c_accent-n3">2:30 p.m. – 3:00 p.m.</strong></p>
<h3 class="m-t_0 c_acc font_display font_medium  lh_2" id="aortic-regurgitation-3-diagnostic-and-management-challenges-15-minutes">Aortic Regurgitation: 3 Diagnostic and Management Challenges: (15 minutes)</h3>
<pre>Associated or not Dilatation of the Aorta
Asymptomatic vs Symptomatic
EF Low/Intermediate vs Normal  
</pre>
<p class="lh_1"><strong>Rick A. Nishimura, MD, MACC</strong><br>
<em class="c_black-7 font-size_down">Rochester, MN</em></p>
<hr class="br-t_1 br_0 br_dashed br_primary m-y_5 m-x_n2">
<h3 class="m-t_0 c_acc font_display font_medium  lh_2" id="critical-commentary-15-minutes-1">Critical Commentary: (15 minutes)</h3>
<p class="lh_1"><strong>Drs. Ismail El-Hamamsy, David H. Adams, Robert O. Bonow, Patrick T. O’Gara, Josep Rodes-Cabau and Samin K. Sharma</strong></p>
<hr class="br-t_1 br_0 br_dashed br_primary m-y_5 m-x_n2">
<p class="m-b_2"><strong class="c_accent-n3">3:00 p.m. – 3:30 p.m.</strong></p>
<h3 class="m-t_0 c_acc font_display font_medium  lh_2" id="the-dilated-thoracic--abdominal-aorta-and-complicating-dissection-evolving-understanding-of-the-basic-biology--management-presentation-15-minutes">The Dilated Thoracic &amp; Abdominal Aorta and Complicating Dissection Evolving Understanding of the Basic Biology &amp; Management Presentation: (15 minutes)</h3>
<p class="lh_1"><strong>Valentin Fuster, MD, PhD, MACC</strong><br>
<em class="c_black-7 font-size_down">New York, NY</em></p>
<hr class="br-t_1 br_0 br_dashed br_primary m-y_5 m-x_n2">
<h3 class="m-t_0 c_acc font_display font_medium  lh_2" id="critical-commentary-15-minutes-2">Critical Commentary: (15 minutes)</h3>
<p class="lh_1"><strong>Ismail El-Hamamsy, MD, PhD,</strong><br>
<em class="c_black-7 font-size_down">New York, NY</em></p>
<hr class="br-t_1 br_0 br_dashed br_primary m-y_5 m-x_n2">
<p class="m-b_2"><strong class="c_accent-n3">3:30 p.m. – 3:50 p.m.</strong></p>
<h3 class="m-t_0 c_acc font_display font_medium  lh_2" id="break-3">Break</h3>
<h2 class="font_medium c_acc-n2" id="session-viii-management-of-mitral-regurgitation-tricuspid-regurgitation-and-hypertrophic-cardiomyopathy">Session VIII: Management of Mitral Regurgitation, Tricuspid Regurgitation and Hypertrophic Cardiomyopathy</h2>
<p class="lh_1"><strong>Chair: David H. Adams, MD, FACC</strong></p>
<hr class="br-t_1 br_0 br_dashed br_primary m-y_5 m-x_n2">
<p class="m-b_2"><strong class="c_accent-n3">3:50 p.m. – 4:20 p.m.</strong></p>
<h3 class="m-t_0 c_acc font_display font_medium  lh_2" id="mitral-regurgitation-3-diagnostic-and-management-challenges">Mitral Regurgitation: 3 Diagnostic and Management Challenges: (15 minutes)</h3>
<pre>- Primary vs Secondary
- Asymptomatic vs Symptomatic
- EF Low/Intermediate vs Normal
</pre>
<p class="lh_1"><strong>Patrick T. O’Gara, MD, MACC</strong><br>
Boston, MA</p>
<h3 class="m-t_0 c_acc font_display font_medium  lh_2" id="critical-commentary-15-minutes-3">Critical Commentary: (15 minutes)</h3>
<p class="lh_1"><strong>Drs. Robert O. Bonow, Rick A. Nishimura, Josep Rodes-Cabau &amp; Samin K. Sharma</strong><br>
</p>
<hr class="br-t_1 br_0 br_dashed br_primary m-y_5 m-x_n2">
<p class="m-b_2"><strong class="c_accent-n3">4:20 p.m. – 4:50 p.m.</strong></p>

<h3 class="m-t_0 c_acc font_display font_medium  lh_2" id="tricuspid-regurgitation-3-diagnostic-and-management-challenges">Tricuspid Regurgitation: 3 Diagnostic and Management Challenges</h3>
<pre>- Primary vs Secondary to Pulmonary Hypertension
- Residual from Previous Left Sided Valvular Surgery or not
- Symptomatic with RVEF Low/Intermediate vs Normal  
</pre>
<p class="lh_1"><strong>Josep Rodes-Cabau, MD</strong><br>
<em class="c_black-7 font-size_down">Quebec, QB, Canada</em></p>
<hr class="br-t_1 br_0 br_dashed br_primary m-y_5 m-x_n2">
<h3 class="m-t_0 c_acc font_display font_medium  lh_2" id="critical-commentary-15-minutes-4">Critical Commentary: (15 minutes)</h3>
<p class="lh_1"><strong>Drs. Robert O. Bonow, Rick A. Nishimura, Patrick T. O’Gara and Samin K. Sharma</strong></p>
<hr class="br-t_1 br_0 br_dashed br_primary m-y_5 m-x_n2">
<p class="m-b_2"><strong class="c_accent-n3">4:50 p.m. – 5:20 p.m.</strong></p>
<h3 class="m-t_0 c_acc font_display font_medium  lh_2" id="hypertrophic-cardiomyopathy--5-challenging-questions-geneticsacquired-myectomy-types-cd-apicalaneurysm-presentation-15-minutes">Hypertrophic Cardiomyopathy – 5 Challenging Questions Genetics/Acquired, Myectomy Types, CD, Apical/Aneurysm Presentation: (15 minutes)</h3>
<p class="lh_1"><strong>Rick A. Nishimura, MD, MACC</strong><br>
<em class="c_black-7 font-size_down">Rochester, MN</em></p>
<hr class="br-t_1 br_0 br_dashed br_primary m-y_5 m-x_n2">
<h3 class="m-t_0 c_acc font_display font_medium  lh_2" id="critical-commentary-15-minutes-5">Critical Commentary: (15 minutes)</h3>
<p class="lh_1"><strong>Drs. Robert O. Bonow, Patrick T. O’Gara, Josep Rodes-Cabau, and Samin K. Sharma</strong></p>
<hr class="br-t_1 br_0 br_dashed br_primary m-y_5 m-x_n2">
<p class="m-b_2"><strong class="c_accent-n3">5:20 p.m.</strong></p>
<h3 class="m-t_0 c_acc font_display font_medium  lh_2" id="adjourn">Adjourn</h3>

    </body>
    </html>